Sarcopenia is defined as a loss of skeletal muscle mass and strength that mostly affects older people. In addition to increasing the risk of falls and fractures, it can also increase the risk of diabetes and cardiovascular disease. Although sarcopenia is highly prevalent in postmenopausal women, there is no definitive evidence supporting its link with the decline in estrogen during the menopause transition. Multiple small-scale studies have been conducted to assess the association between HT use and muscle mass, but their results have been inconsistent.
‘The prolonged use of hormone therapy is associated with higher muscle mass and a lower prevalence of sarcopenia in postmenopausal women.’
This new study, which included more than 4,200 postmenopausal women, is one of the few large-scale studies known to assess the link between use of HT and muscle loss in postmenopausal women. More specifically, it focused on the duration of HT use and its effect on muscle mass and the prevalence of sarcopenia.
“Although not all studies examining an association between hormone therapy and muscle mass have shown positive results, this large cross-sectional study demonstrated a relationship between extended use of hormone therapy and both greater muscle mass and lower risk of sarcopenia in women aged younger than 65 years and with a body mass index less than 25 kg/m2,” says Dr. Stephanie Faubion, NAMS medical director. “The mechanism by which estrogen protects muscle mass remains unclear, and additional study is needed.”